Topotecan
- Generic Name
- Topotecan
- Brand Names
- Hycamtin, Potactasol, Topotecan Hospira
- Drug Type
- Small Molecule
- Chemical Formula
- C23H23N3O5
- CAS Number
- 123948-87-8
- Unique Ingredient Identifier
- 7M7YKX2N15
- Background
An antineoplastic agent used to treat ovarian cancer. It works by inhibiting DNA topoisomerases, type I.
- Indication
用于小细胞肺癌（SCLC）和一线治疗失败的晚期转移性卵巢癌。
- Associated Conditions
- Acute Myeloid Leukemia, Ewing's Sarcoma, Refractory Neuroblastoma, Metastatic Rhabdomyosarcoma, Recurrent Stage IVB Cervical Cancer, Refractory CNS lymphoma, Refractory CNS malignancy, Refractory, metastatic Ovarian cancer, Relapsed Platinum Sensitive Small Cell Lung Cancer (SCLC)
Medtronic's Symplicity Spyral RDN Catheter Receives CMS Transitional Pass-Through Payment
• The Centers for Medicare & Medicaid Services (CMS) has granted transitional pass-through (TPT) payment for Medtronic's Symplicity Spyral renal denervation (RDN) catheter.
• The TPT payment, effective January 1, 2025, for up to three years, aims to improve patient access to innovative technologies like the Symplicity Spyral RDN system.
• The Symplicity Spyral RDN system is a minimally invasive procedure that delivers radiofrequency energy to nerves near the kidneys to lower blood pressure.
• The TPT program reduces barriers for Medicare beneficiaries to access critical healthcare innovations shortly after products receive FDA approval.
Sidney Hecht Honored for Pioneering Work Linking Chemistry and Biology to Combat Disease
• Sidney Hecht received the Arizona Bioscience Pioneer Award for Lifetime Achievement for merging biology and chemistry to improve human health.
• Hecht's research at ASU's Biodesign Center focuses on mitochondrial disorders, particularly Friedreich’s ataxia, a genetic neuromuscular disease.
• Hecht played a key role in developing Hycamtin, a chemotherapy drug for ovarian and lung cancer, and studied the anti-tumor agent Bleomycin.
• His center has developed compounds that redirect electrons in dysfunctional respiratory chains, with one in clinical trials for Friedreich’s ataxia.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath